0.0020EUR0.00%Mkt Cap: 1.31M EURP/E: —Last update: 2026-05-29
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (O…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.31M EUR
Enterprise Value24.33M EUR
Revenue (TTM)-2.39M EUR
Gross Profit-2.39M EUR
Net Income (TTM)-28.78M EUR
Revenue/Share-0.0060 EUR
Last Price0.0020 EUR
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees7
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINBE0974280126
Valuation
P/E (Trailing)—
P/E (Forward)-0.04
PEG—
EV/EBITDA-5.06
EV/Revenue-10.19
P/S-0.55
P/B-0.06
EPS (TTM)-0.02
EPS (Forward)-0.05
52W Range
0.001625% of range0.0032
52W High0.0032 EUR
52W Low0.0016 EUR
Profitability
Gross Margin0.00%
Oper. Margin-70700.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE125.60%
ROA-301.06%
Growth
Revenue Growth-100.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.47M EUR
CapEx (TTM)—
FCF Margin145.17%
FCF Yield-265.38%
Net Debt23.03M EUR
Net Debt/EBITDA-4.79
Balance Sheet
Debt/Equity-1.23
Current Ratio0.53
Quick Ratio0.50
Book Value/Sh-0.0360 EUR
Cash/Share0.0010 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.652.86M
Float603.17M
Insiders14.14%
Institutions1.87%
Technical
SMA 500.0022 (-10.6%)
SMA 2000.0024 (-15.5%)
Beta-1.60
S&P 52W Chg27.94%
Avg Vol (30d)1.44M
Avg Vol (10d)466.91K
Technical Indicators
RSI (14)39.4
MACD-0.0001
MACD Signal-0.0000
MACD Hist.-0.0000
BB Upper0.0024 EUR
BB Middle0.0022 EUR
BB Lower0.0020 EUR
BB Width18.04%
ATR (14)0.0002 EUR
Vol Ratio (20d)0.00x